Innovative Access Program

Through the Innovative Access Program we collaborate closely with academic experts, bringing our cutting edge antibody discovery technologies to the heart of novel target research. The extraordinary diversity of our immune repertoires streamlines target validation, transforming novel proteins into next generation therapeutic antibody programs.

argenx’s Innovative Access Program with the Universite Catholique de Louvain / de Duve Institute has led to pioneering new work in the field of immuno-oncology, patented inventions on the novel immune checkpoint target GARP, and a comprehensive preclinical program with exciting development potential in oncology.

Two additioanal IAP success stories were announced. The first one is ARGX-116, which was discovered in close collaboration with disease biology experts from Staten Biotechnology, an emerging biotechnology company specialized in the field of
dyslipidemia. In addition, we entered into a collaboration under our Innovative Access Program with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia and antibody mediated rejection following organ transplantation. 

Contact us if you would like to discuss ways to bring argenx antibody discovery expertise to your academic research.